- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05551455
Endocrinological and Physiological Responses to Short-term Reduced Carbohydrate Availability in Males
Investigating the Endocrinological and Physiological Responses to Short-term Reduced Carbohydrate Availability in Males.
Study Overview
Status
Detailed Description
Rationale:
The primary research question associated with this study is 'What is the impact of an acute period of low carbohydrate availability upon associated physiological and endocrinological markers in a cohort of healthy males?'
Extensive research has been conducted since the 1970s to determine the aetiology behind the concurrent impairment of reproductive function and low bone mineral density that is commonly observed in exercising females (De Souza et al., 2014). This research has determined that chronic low energy availability ('LEA' - the energy available from diet after energy used in exercise has been subtracted) is the key determining factor for the endocrine and physiological responses observed in the Female Athlete Triad (De Souza et al., 2014) model. However, whilst the Male Athlete Triad (Nattiv et al., 2021) and RED-S (Mountjoy et al., 2018) models identify the likely impact of LEA upon males, equivalent research identifying the physiological effects of this state in males is far behind that of females.
Moreover, whilst low energy availability has been identified as the key driver of the physiological dysregulations identified in the Female/Male Athlete Triad and RED-S models, much of the existing research has not adequately delineated between the impact of low energy availability, per se, and low carbohydrate availability. Recent research suggests that low carbohydrate availability, with or without the presence of LEA, may be a driver of the physiological dysregulations identified within the aforementioned models. For example, McKay et al (2021) have shown altered iron and immune responses and impaired exercise performance following 6-days of low carbohydrate (50 - 100 g/day) but ~normal energy availability (40 kcal•kg FFM-1•day-1), whilst no changes were apparent in a LEA (15 kcal•kg FFM-1•day-1, 60% carbohydrate) and a control group. Similarly, Heikura et al (2020) have recently shown that over 3.5 weeks, a ketogenic diet impairs markers of bone turnover compared to an energy-matched high carbohydrate diet in highly trained athletes.
Given that exercise and nutritional interventions are key for improving weight-loss and health of the general population, understanding how reduced energy and/or carbohydrate availability may affect male endocrinology and physiology is of the utmost importance. The effects and mechanisms by which low energy and/or carbohydate availability influences male physiological function therefore requires further research using well-controlled experimental research designs.
We have recently conducted a study that aimed to understand the broad physiological, endocrine and muscular responses to a period of five-days of low energy availability (analysis of samples is ongoing). The proposed study therefore now aims to extend the scope of our research to investigate the impact of four- days of low carbohydrate availability using a low-carbohydrate, high-fat diet in the presence of adequate energy availability to address this gap in the literature.
Objectives:
Primary:
To investigate the physiological responses of adult males to low carbohydrate availability whilst in energy balance over 4-days (~96 hrs, spanning five testing mornings), in contrast to an equivalent period of controlled energy balance with 'normal' carbohydrate availability in relation to muscle and endocrine parameters.
Secondary:
To investigate the wider physiological responses of adult males to low carbohydrate availability (whilst in energy balance) over 4-days (~96 hrs, spanning five testing mornings), compared to an equivalent period in controlled 'normal' carbohydrate availability in relation to whole-body physiological and metabolic status as well as body composition changes.
Study Methods:
Using a randomised cross-over design, participants will complete two interventions that will elicit conditions of 'normal' (NEA) and 'low' (LEA) carbohydrate availability whilst in energy balance, with a 10-day washout period in between conditions. Body composition changes and markers of bone turnover and reproductive health will be assessed, along with further physiological parameters.
Sample Size:
Sample size was determined based upon the primary outcome measure of Free Circulating Testosterone, the least sensitive primary outcome measures of the study.
The findings of Koehler et al (2016) were used to estimate required sample size for this study. Koehler et al (2016) reported a non-significant (P >0.05) change in Testosterone following four days of Low Energy Availability (with exercise) at 15 kcal/kg FFM/day (LEA + Ex: Pre 5.27 ± 0.46, Post 4.46 ± 0.96 ng.ml-1), compared to a control group with exercise (C + Ex: Pre 4.98 ± 0.47 Post 4.92 ± 0.53 ng.ml-1). However, a large effect size for the reduction in testosterone concentrations for LEA + Ex compared to C + Ex (d = 1.36) was observed/calculated. Therefore a post-hoc power analysis was conducted, revealing a power (1-β err probability) of 0.759 for the sample size of N = 6. To replicate these findings with greater statistical power (α err prob 0.05, 1-β err prob > 0.9) would require 8 participants, with 9 participants required to factor for a potential 10% dropout rate in participants commonly observed.
Quality:
The research plan has been reviewed internally within the research team at Liverpool John Moores University. The researcher's associated with this study and associated with the review of the study protocol are all members of staff (or a PhD Student) within the Liverpool John Moores University Research Institute for Sport & Exercise Sciences (RISES). In the 2014 RISES (LJMU) submitted 34.75 FTE (full time equivalent) to Unit of Assessment 26 (UoA26) and attained a GPA (Grade Point Average) of 3.57. Placed second on GPA in the UoA, RISES became the leading centre for Sport and Exercise Science Research Quality in the UK (4* - 61% of all activity world leading, 3* - 36% of all activity internationally excellent standard). RISES submitted the largest volume of 4* outputs (n=60) in the UoA, had 90% of the impact activity rated at 4* and had 100% of the environment rated as 4*. Importantly, out of 1,911 submissions in all 36 UoA's RISES came 11th in the entire UK for GPA achieved at REF2014, putting RISES (LJMU) amongst Oxford, UCL, LSE and Cambridge in the league tables for this metric. This makes RISES perfectly qualified to assess this research project.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jose L Areta
- Phone Number: +441519046230
- Email: J.L.Areta@ljmu.ac.uk
Study Contact Backup
- Name: Harry L Taylor
- Email: H.L.Taylor@2019.ljmu.ac.uk
Study Locations
-
-
Merseyside
-
Liverpool, Merseyside, United Kingdom, L3 3AF
- Liverpool John Moores University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Gender/Sex: Male
- Age:18-40
- Healthy (as determined by pre-participation questionnaires)
- Regularly Exercising/Aerobically trained (3 + times/week, VO2max >50 ml/kg/min), as determined through participant self-identification via recruitment email/verbal communication and baseline assessment of VO2max)
- Weight-stable (within 2 kg) for the past 6-months
Exclusion Criteria:
- Gender/Sex: Female/Other
- Age - < 18 - > 40
- Health - Deemed unable to perform exercise (assessed via PAR-Q)
- Current smoker.
- Medical Condition - Those with any previous diagnosis of; Osteoporosis/low bone mineral density, cardio-vascular disease, Diabetes Mellitus, Cerebrovascular Disease, blood-related illness/disorder, Asthma or other respiratory illness/disorder, Liver Disease, Kidney Disease, gastrointestinal disease, Eating Disorder or Disordered Eating. Those currently taking prescription medication or unwell with a cold or virus at the time of participation.
- Those unwilling to adhere to the study's methodological requirements (including adhering to alterations in diet and training - inc. alcohol abstention) from the day prior to intervention onset (24 hrs pre-intervention) to completion of follow-up assessments (day 5).
- Those following a restrictive diet (e.g. vegans)
- Those with food allergies and/or food intolerances
- Training status - Does not train 3 + times/week (over past 6 months on average) and/or have a VO2max >50 ml/kg/min.
- Any athletes that may be tested for substances on the WADA banned substances list
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Normal Carbohydrate Availability
Participants will complete a supervised morning cycling session daily (each morning for five days) to achieve a 15 kcal/kg FFM/day exercise energy expenditure, with samples collected pre-, during- and post-exercise. Participants will then be provided (daily) with all subsequent dietary intake for the intervention period. In the Normal Carbohydrate Availability trial arm, participants will be provided with 60 kcal/kg FFM/day of energy intake, to elicit a net energy availability of 45 kcal/kg FFM, with ~60% of this energy intake from carbohydrates. The intervention will last for four days, spanning five testing mornings (i.e. trial begins following fasted baseline assessments on morning 1, finishing with final sample collection on morning 5). |
Energy Intake provision (60 kcal/kg FFM/day) to elicit 'normal' energy availability (45 kcal/kg FFM/day), with 60% from carbohydrates.
Other Names:
|
Experimental: Low Carbohydrate Availability
Participants will complete a supervised morning cycling session daily (each morning for five days) to achieve a 15 kcal/kg FFM/day exercise energy expenditure, with samples collected pre-, during- and post-exercise. Participants will then be provided (daily) with all subsequent dietary intake for the intervention period. In the Low Carbohydrate Availability trial arm, participants will be provided with 60 kcal/kg FFM/day of energy intake, to elicit an energy availability of 45 kcal/kg FFM, with ~1.5 g/kg provided from carbohydrate and ~70-80% of energy intake in the form of fat. The intervention will last for four days, spanning five testing mornings (i.e. trial begins following fasted baseline assessments on morning 1, finishing with final sample collection on morning 5). |
Energy Intake provision (60 kcal/kg FFM/day), with 1.5 g/kg of carbohydrate and 70-80% fat intake, to elicit 'low' carbohydrate availability in energy balance (45 kcal/kg FFM/day).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in blood bone turnover markers: ß-CTX (Bone Resorption)
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes in blood-borne bone (re)modelling marker ß-CTX (Bone Resorption) following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in blood bone turnover markers: P1NP (Bone Formation)
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes in blood-borne bone (re)modelling marker P1NP (Bone Formation)
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in blood metabolites/hormones: Testosterone
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes to circulating testosterone concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 2, 3, 4 & 5 per intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in resting substrate utilisation
Time Frame: Days 1, 3 and 5 of each intervention
|
Analysis of changes in resting substrate utilisation.
Assessed using indirect calorimetry.
|
Days 1, 3 and 5 of each intervention
|
Changes in sub-maximal Exercise Energy Expenditure
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes in sub-max exercise energy expenditure and substrate utilisation at standardised exercise intensities.
Assessed using indirect calorimetry.
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in sub-maximal exercise substrate utilisation
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes in sub-max exercise energy expenditure and substrate utilisation at standardised exercise intensities.
Assessed using indirect calorimetry.
|
Days 1, 2, 3, 4 & 5 per intervention
|
Immune function
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes to saliva-based markers of immune function
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in Initial Orthostatic Hypotension (IOH)
Time Frame: Pre- and post-intervention (days 1 and 5) for both intervention
|
Analysis of changes in IOH, assessed via blood pressure finometry and questionnaire
|
Pre- and post-intervention (days 1 and 5) for both intervention
|
Change in Profile of Mood States
Time Frame: Pre- and post-intervention (days 1 and 5) per intervention
|
Analysis of changes in Psychological/mood, assessed via the POMS-40 questionnaire
|
Pre- and post-intervention (days 1 and 5) per intervention
|
Change in subjective hunger
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analsis of changes in subjective hunger, assessed via visual analogue scales
|
Days 1, 2, 3, 4 & 5 per intervention
|
Change in sexual drive/libido
Time Frame: Pre- and post-intervention (days 1 and 5)
|
Analysis of subjective sex-drive/libido changes, assessed via visual analogue scale
|
Pre- and post-intervention (days 1 and 5)
|
Physical activity energy expenditure (PAEE)
Time Frame: Continuous monitoring during intervention period (5-days)
|
Analysis of PAEE alterations, assessed via wrist-worn accelerometers (acti-watch)
|
Continuous monitoring during intervention period (5-days)
|
Sleep duration and quality
Time Frame: Continuous monitoring during intervention period (5-days)
|
Analysis of sleep alterations, assessed via wrist-worn device and sleep diary (collectively quantified by analysis of sleep duration, sleep latency, time of sleep onset, no of wakes during night, subjective sleep quality visual analogue scale)
|
Continuous monitoring during intervention period (5-days)
|
Changes in Body Composition: Body Mass (kg)
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in Body Composition: Body Mass Index (kg/m^2)
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in Body Composition: Fat Mass (kg)
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in Body Composition: Body Fat Percentage (%)
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in Body Composition: Fat Free Mass (kg)
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in Body Composition: Skeletal Muscle Mass (kg)
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in Body Composition: Total Body Water (l)
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in Body Composition: Total Body Water (%)
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in Body Composition: Extra-cellular Water (l)
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in Body Composition: Extra-cellular Water (%)
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in Body Composition: Extra-cellular Water/Total Body Water ratio
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in blood metabolites/hormones: Ketones
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes to circulating ketones concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in blood metabolites/hormones: Glucose
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes to circulating glucose concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in blood metabolites/hormones: Free fatty Acids
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes to circulating free fatty acid concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in blood metabolites/hormones: Insulin
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes to circulating insulin concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in blood metabolites/hormones: Cortisol
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes to circulating cortisol concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in blood metabolites/hormones: HDL
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes to circulating HDL concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in blood metabolites/hormones: LDL
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes to circulating LDL concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in blood metabolites/hormones: glycerol
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes to circulating glycerol concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in blood metabolites/hormones: Leptin
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes to circulating Leptin concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 2, 3, 4 & 5 per intervention
|
Changes in blood metabolites/hormones: IGF-1
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes to circulating IGF-1 concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 2, 3, 4 & 5 per intervention
|
Alterations to skeletal muscle glycogen
Time Frame: Days 1 & 5 per intervention (pre-post)
|
Assessment of alterations in skeletal muscle glycogen content
|
Days 1 & 5 per intervention (pre-post)
|
Alterations to Intra-muscular lipid profile: lipid droplet content
Time Frame: Days 1 & 5 per intervention (pre-post)
|
Assessment of alterations in lipid droplet content
|
Days 1 & 5 per intervention (pre-post)
|
Alterations to Intra-muscular lipid profile: lipid droplet morphology
Time Frame: Days 1 & 5 per intervention (pre-post)
|
Assessment of alterations in lipid droplet morphology
|
Days 1 & 5 per intervention (pre-post)
|
Alterations to Intra-muscular lipid profile: lipid droplet associated proteins
Time Frame: Days 1 & 5 per intervention (pre-post)
|
Assessment of alterations in lipid droplet associated proteins
|
Days 1 & 5 per intervention (pre-post)
|
Resting Metabolic Rate
Time Frame: Days 1, 3 and 5 of each intervention
|
Analysis of changes to Resting Metabolic Rate (kcal/day) following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 3 and 5 of each intervention
|
Changes in blood metabolites/hormones: Triiodothyronine (T3)
Time Frame: Days 1, 2, 3, 4 & 5 per intervention
|
Analysis of changes to circulating T3 concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability
|
Days 1, 2, 3, 4 & 5 per intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jose L Areta, Liverpool John Moores University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 22/SPS/026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Energy Supply; Deficiency
-
Swiss Paraplegic Centre NottwilCompletedEnergy Supply; DeficiencySwitzerland
-
United States Army Research Institute of Environmental...RecruitingStress, Physiological | Energy Supply; Deficiency | Energy Supply; Deficiency, SevereUnited States
-
Liverpool John Moores UniversityAlliance for Potato Research and EducationCompletedEnergy Supply; Deficiency | Energy Balance | Energy AvailabilityUnited Kingdom
-
Brock UniversityNatural Sciences and Engineering Research Council, CanadaWithdrawnBone Loss | Energy Supply; DeficiencyCanada
-
Federal University of Minas GeraisConselho Nacional de Desenvolvimento Científico e Tecnológico; Fundação de...UnknownPostoperative Complications | Cancer | Surgery | Energy Supply; DeficiencyBrazil
-
University of BathUniversity of NottinghamActive, not recruitingAdiposity | Metabolic Disturbance | Fasting | Energy Supply; DeficiencyUnited Kingdom
-
SourseCitruslabsActive, not recruitingMood | Energy Supply; Deficiency | B12 Deficiency VitaminUnited States
-
Loughborough UniversityCompletedBone Resorption | Energy Supply; Deficiency | Female Athlete Triad | Relative Energy Deficiency in Sport | Bone AtrophyUnited Kingdom
-
Jens Rikardt AndersenDepartment of Oncology, Rigshospitalet, Blegdamsvej 9, 2100 CopenhagenUnknownWeight Loss | Abdominal Cancer | Radiotherapy; Complications | Protein Deficiency | Energy SupplyDenmark
-
HEIDEGGER CPAalborg UniversityRecruitingHyperglycemia | Hypoglycemia | Critical Illness | Protein Deficiency | Energy Supply; Deficiency, SevereSwitzerland
Clinical Trials on Nutritional/dietary intake manipulation ('Normal')
-
Ohio State UniversityRecruitingHeart Failure With Preserved Ejection FractionUnited States
-
Ohio State UniversityCompletedMetabolic Syndrome XUnited States
-
University of CopenhagenMaastricht University Medical CenterRecruitingDiet, Healthy | Protein DeficiencyDenmark
-
Heidelberg UniversityCompletedCoronary Artery Disease | Stroke | Metabolic Syndrome | Cardiovascular Risk Factors | Lifestyle ModificationParaguay
-
University of the PunjabCompleted
-
Medical University of ViennaCompleted
-
University Hospital, ToulouseCompleted
-
Sara Arranz MartinezMUTUALIA S.L.; OSARTEN KOOPERATIBA ELKARTEACompleted
-
University of NottinghamDLR German Aerospace Center; Jozef Stefan Institute; European Commission; KTH Royal...CompletedHypoxia | Bone Resorption
-
University of California, San DiegoRecruiting